Cabozantinib加Nivolumab治疗非透明细胞肾细胞癌患者：II期试验的最新结果》更正 [Eur. Urol. 86(2) (2024) 90-94]

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2024-10-18 DOI:10.1016/j.eururo.2024.10.002

Kelly N. Fitzgerald, Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer

{"title":"Cabozantinib加Nivolumab治疗非透明细胞肾细胞癌患者：II期试验的最新结果》更正 [Eur. Urol. 86(2) (2024) 90-94]","authors":"Kelly N. Fitzgerald, Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer","doi":"10.1016/j.eururo.2024.10.002","DOIUrl":null,"url":null,"abstract":"The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events. Correct values were included the corresponding supplemental tables 2 and 4, and are stated here: Treatment-related AEs of any grade were experienced by 40 patients (100%); grade 3-4 AEs were experienced by 20 patients (50%). Treatment-related grade 3-4 AST and ALT elevations were 13% and 15% respectively.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"29 1","pages":""},"PeriodicalIF":25.3000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]\",\"authors\":\"Kelly N. Fitzgerald, Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer\",\"doi\":\"10.1016/j.eururo.2024.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events. Correct values were included the corresponding supplemental tables 2 and 4, and are stated here: Treatment-related AEs of any grade were experienced by 40 patients (100%); grade 3-4 AEs were experienced by 20 patients (50%). Treatment-related grade 3-4 AST and ALT elevations were 13% and 15% respectively.\",\"PeriodicalId\":12223,\"journal\":{\"name\":\"European urology\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":25.3000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.eururo.2024.10.002\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eururo.2024.10.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

作者感到遗憾的是，文中对不良事件（AE）发生率的估计值有四处错误，与相应表格中的正确估计值不符。具体而言，文中对以下治疗相关不良事件发生率的估计值有误：1）任何级别的不良事件；2）3-4 级不良事件；3）3-4 级 AST 事件；4）3-4 级 ALT 事件。正确值已列入相应的补充表 2 和表 4，并在此予以说明：40名患者（100%）发生了任何级别的治疗相关不良反应；20名患者（50%）发生了3-4级不良反应。治疗相关的 3-4 级 AST 和 ALT 升高分别为 13% 和 15%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]

The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events. Correct values were included the corresponding supplemental tables 2 and 4, and are stated here: Treatment-related AEs of any grade were experienced by 40 patients (100%); grade 3-4 AEs were experienced by 20 patients (50%). Treatment-related grade 3-4 AST and ALT elevations were 13% and 15% respectively.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.